electroCore reports Q3 EPS (40c), consensus (40c)

Reports Q3 revenue $8.7M, consensus $7.88M. “Prescription sales continued to accelerate in this quarter driven by sales within the department of Veteran Affairs (“VA”) market. gammaCore and Quell Fibromyalgia each showed strong growth in the VA with gammaCore sales increasing 16% over the same period in 2024 and Quell contributing $530,000 in VA revenues and $595,000 of total product sales in the quarter,” commented Dan Goldberger, CEO of electroCore (ECOR). “With Truvaga revenue also hitting a record high of $1.7 million in the quarter, we are increasing our revenue guidance to $31.5 million to $32.5 million for the full year 2025.”